Proceedings of The Physiological Society

University of Edinburgh (2011) Proc Physiol Soc 25, PC27

Poster Communications

Inhibition of Rho Kinase by 5-HT in 5-HT-induced constriction of isolated Bovine pulmonary arteries

R. McCallum1, A. M. Shaw1, A. MacDonald1, A. Corbett1

1. Biological sciences, Glasgow Caledonian University, Glasgow, United Kingdom.

The Rho-A/Rho-kinase pathway plays an important role in agonist -induced constriction of vascular smooth muscle. Indeed inhibition of Rho-kinase has been promoted as a putative management therapy in pulmonary hypertension (Abe et al, 2004). Rho-kinase can be activated by agonist receptors that couple to G12/13 (Fukata et al, 2001) and/or by elevated intracellular calcium (Ayeman et al, 2003). In bovine pulmonary arteries 5-HT induced constriction is mediated by the 5-HT2A and 5-HT1B receptors (McKenzie et al, 2010). The present study investigated the role of Rho-kinase in 5-HT-induce constriction of bovine pulmonary arteries. Bovine lungs from animals under twenty months were obtained fresh from the local abattoir. Ring segments (0.3-0.5cm in diameter), dissected from the 5th. Arterial generation were mounted in 5 ml organ baths suspended between stainless steel hooks in Krebs-Henseleit buffer (37oC) under a tension of 2 g and gassed with a mixture of O2:CO2 95%/5% v/v. Tissues were allowed to equilibrate for 1 hour before the addition of drugs. All tissues were first contracted with 60 mM KCl. After washing, cumulative concentration response curves (CRCs) to 5HT or a single constriction to the 5-HT2A agonists DOI (10nM) or TCB (1µM) were constructed in the absence or presence of the Rho kinase inhibitors Y27632 (30µM) or H1152 (10µM). CRC to 5-HT were further examined in presence of the 5-HT1B (SB216641, 3μM) and 5-HT1D (BRL15572, 10nM) receptor antagonists or the selective serotonin re-uptake inhibitor paroxetine (10nM) alone or in the presence of Y27632. The concentration response curve for 5-HT-induced constriction was unaffected by the Rho-kinase inhibitors Y27632 or H1152. In contrast constriction induced by the 5-HT2A agonists DOI was reduced by 58% (from 95.28±6.62 to 39.88±4.02, n=4, values expressed as percentage of 60mM KCL contraction) by Y27632. The 5-HT1B receptor antagonist SB216641 shifted the CRC for 5-HT to the right (control EC50=-5.915±0.096, SB216641 EC50=-4.771±0.102, n=7) and reduced the maximum response by 20% (from 188.2±7.90 to 149.8±9.83, n=7) and this response was unaffected by the further addition of Y27632. The presence of the 5-HT1D receptor antagonist (BRL15572) produced a 26% increase in tone (from 190.4±9.44 to 239±14.76, n=7), the selective serotonin re-uptake inhibitor (paroxetine) produced a similar potentiation of 24% to the maximal contraction of the 5-HT CRC (from 174.4±3.79 to 217.1±8.6, n=4). The further addition of Y27632 reduced the maximum response by approximately 36-42% (from 239±14.76 to 153±9.77, n=7, in the presence of BRL15572 and from 217.1±8.6 to 125.1±7.45, n=4, in the presence of paroxetine). These observations suggest that 5-HT acting through the 5-HT1D receptor and/or the selective serotonin reuptake mechanism may inhibit the involvement of Rho-kinase in 5-HT-induced constriction of BPA.

Where applicable, experiments conform with Society ethical requirements